The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
The company posted net profit of Rs.62.17 crores for the period ended December 31, 2019.
The agreement targets a long-standing technical hurdle in the field: maintaining chemical purity as RNA constructs extend beyond 100 nucleotides
These check-ups will be conducted through ESIC’s extensive network of hospitals, with a focus on early diagnosis, preventive healthcare, and continuous health monitoring
The deal brings SAI — a key distributor serving pharmaceutical and nutraceutical manufacturers — into the Safic-Alcan Group’s expanding Asia footprint
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
The private funding rose 38% amid growing international collaborations and CDMO demand
The renewal covers two versions of the IQOS device and three HEETS tobacco variants
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
The company posted revenue of €1,267 million, up 6% on a constant currency basis
Subscribe To Our Newsletter & Stay Updated
